Key result
Transdermal oestradiol linked to increased arterial and total limb blood flow over 1 year.
Why the study?
The influence of transdermal oestradiol therapy on vascular dynamics in men with advanced prostate cancer was not well characterized.
Does transdermal oestradiol therapy alter vascular flow in men with advanced prostate cancer?
Observational (n=20)
Does transdermal oestradiol therapy alter vascular flow in men with advanced prostate cancer?
Transdermal oestradiol therapy in men with prostate cancer increases arterial flow and causes a transient decrease in arterial compliance, potentially explaining early cardiovascular toxicity and later cardioprotective effects.
Transdermal oestradiol may affect vascular dynamics in advanced prostate cancer; hypothesis-generating pilot data that leaves open clinical implications pending larger trials.
OBJECTIVE: To report the influence of transdermal oestradiol therapy on the vascular dynamics of men with advanced prostate cancer. PATIENTS AND METHODS: Twenty patients with newly diagnosed locally advanced or metastatic prostate cancer (10 each) were treated using transdermal oestradiol patches. The vascular flow was assessed 6-monthly before and during a year of therapy using arterial and venous Doppler and duplex ultrasonography, arterial and venous photoplethysmography and opto-electronic plethysmography. RESULTS: Arterial flow, as measured by the mean and peak systolic velocities and photoplethysmography, significantly increased over time. Arterial compliance initially decreased but had normalized after 12 months. The venous variables were unaffected. As a result, the total limb blood flow and the capillary filtration rate were significantly increased. CONCLUSION: Transdermal oestradiol therapy causes an increase in arterial but not venous flow, and an initial decrease in arterial compliance, which adapts to the physiological range with time. It is possible that these changes may account for the increase in cardiovascular toxicity seen in the early phase of oestrogen therapy, and the cardioprotective effect that accrues thereafter.
No takes yet. Share an insight, caveat, or question.
Ockrim et al. (2006) conducted an observational in Advanced prostate cancer (n=20). Transdermal oestradiol therapy was evaluated on Vascular flow (arterial and venous dynamics). Transdermal oestradiol therapy significantly increased arterial flow and total limb blood flow over 1 year, with an initial decrease in arterial compliance that normalized by 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: